Celyad SA (CYAD): Price and Financial Metrics
Celyad SA (CYAD)
Today's Latest Price: $10.35 USD
0.53 (-4.87%)
Updated Dec 13 6:55pm
Add CYAD to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
See all "A" rated Strong Buy stocks
CYAD Stock Summary
- With a price/sales ratio of 34.58, Celyad Sa has a higher such ratio than 96.62% of stocks in our set.
- With a year-over-year growth in debt of 303.59%, Celyad Sa's debt growth rate surpasses 94.18% of about US stocks.
- As for revenue growth, note that CYAD's revenue has grown 2,060.55% over the past 12 months; that beats the revenue growth of 99.56% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Celyad Sa, a group of peers worth examining would be PRQR, MRUS, ARPO, MDWD, and STML.
- Visit CYAD's SEC page to see the company's official filings. To visit the company's web site, go to www.celyad.com.
CYAD Daily Price Range
CYAD 52-Week Price Range
CYAD Stock Price Chart More Charts
CYAD Price/Volume Stats
| Current price | $10.35 | 52-week high | $25.36 |
| Prev. close | $10.88 | 52-week low | $8.10 |
| Day low | $10.31 | Volume | 114,200 |
| Day high | $10.90 | Avg. volume | 20,183 |
| 50-day MA | $10.09 | Dividend yield | N/A |
| 200-day MA | $14.76 | Market Cap | 102.18M |
Celyad SA (CYAD) Company Bio
Celyad SA is a leader in engineered cell therapy treatments with clinical programs initially targeting indications in cardiology and oncology. The company was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.
Top Stories View All
3 “Must Own” Online Growth Stocks
Best & Worst Performing Stock Industries for December 13, 2019
Best & Worst Performing Small Cap Stocks for December 13, 2019
Best & Worst Performing Mid Cap Stocks for December 13, 2019
Best & Worst Performing Large Cap Stocks for December 13, 2019
View All Top Stories
Loading social stream, please wait...